XR 303

Drug Profile

XR 303

Alternative Names: Anti-CEA sheep monoclonal antibody - KS Biomedix Holdings; Anti-CEA sheep monoclonal antibody 6H9; KAb201; KS 6H9Chi; KSB 303; KSB-303C; KSB-303P; Sheep anti-CEA monoclonal antibody - KS Biomedix Holdings; SMA CEA - KS Biomedix Holdings; XR303

Latest Information Update: 13 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research UK; Xenova Group
  • Developer Celtic Pharma
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 13 Sep 2010 Discontinued - Phase-I for Colorectal cancer in Malaysia (Parenteral)
  • 13 Sep 2010 Discontinued - Phase-I/II for Pancreatic cancer in Europe (Parenteral)
  • 08 Aug 2007 XR 303 is still in phase I/II trials for Pancreatic cancer in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top